NMRA

Neumora Therapeutics, Inc. Healthcare - Biotechnology Investor Relations →

YES

72.0% BELOW

↑ Moving away Was -73.9% last week

-15% -10% -5% 0% 5% 10% 15%+

Buy Threshold $7.58

14-Week RSI 33

Neumora Therapeutics, Inc. (NMRA) closed at $2.12 as of 2026-02-02, trading 72.0% below its 200-week moving average of $7.58. This places NMRA in the extreme value zone. The stock moved further from the line this week, up from -73.9% last week. The 14-week RSI sits at 33, indicating neutral momentum.

Over the past 77 weeks of data, NMRA has crossed below its 200-week moving average 2 times. On average, these episodes lasted 36 weeks. The average one-year return after crossing below was -86.1%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $360 million, NMRA is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -104.3%. The stock trades at 2.6x book value.

Share count has increased 6.4% over three years, indicating dilution.

Over the past 1.6 years, a hypothetical investment of $100 in NMRA would have grown to $18, compared to $125 for the S&P 500. NMRA has returned -65.6% annualized vs 15.0% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 2 open-market purchases totaling $9,999,954. Notably, these purchases occurred while NMRA is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Growth of $100: NMRA vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After NMRA Crosses Below the Line?

Across 2 historical episodes, buying NMRA when it crossed below its 200-week moving average produced an average return of -79.0% after 12 months (median -73.0%), compared to +18.5% for the S&P 500 over the same periods.

Each line shows $100 invested at the moment NMRA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Insider Buying Activity

2 conviction buys in the past 12 months (purchases over $500K with meaningful position increases).

Date	Insider	Title	Value	Shares	Position +%
2025-10-27	BUROW KRISTINA M	Director and Beneficial Owner of more than 10% of a Class of Security	$4,999,977	1,915,700	+6.0%
2025-10-27	ARCH VENTURE PARTNERS XII, LLC	Beneficial Owner of more than 10% of a Class of Security	$4,999,977	1,915,700	+6.0%

Historical Touches

NMRA has crossed below its 200-week MA 2 times with an average 1-year return of +-86.1% after recovery.

Crossed Below	Recovered	Weeks	Max Depth	1-Year Return	Return Since Touch
Aug 2024	Sep 2024	4	18.3%	-86.1%	-81.8%
Oct 2024	Ongoing	68+	93.9%	Ongoing	-82.7%
Average		36	—	+-86.1%	—

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02